Santiago De Compostela

• A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended
  2023-509747-27-00 4 2023-05-18 Heart failure
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lun … Ended
  2023-505540-19-00 10 2023-04-24 Pulmonary Hypertension Associated with Interstitial Lung Disease
• Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Ped … Ended
  2023-507144-36-00 5 2023-04-20 Juvenile psoriatic arthritis
• A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended
  2022-501362-22-00 10 2023-04-18 Psoriatic Arthritis
• A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended
  2022-501425-20-00 4 2023-04-03 Rheumatoid Arthritis Arthritis Joint Diseases Musculoskeletal Disea
• A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505902-40-00 4 2023-03-28 Heart Failure with Preserved Ejection Fraction
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended
  2024-511089-36-00 4 2023-03-17 Crohn’s disease
• A phase IIa, open label, Single-centre study to assess the initial antifibrotic efficacy, safety, tolerability, pharmacokinetic and pharmaco … Ended
  2022-501464-18-00 4 2023-03-01 Crohn’s disease
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• A clinical study to evaluate mRNA-3705 in Patients with MMA Ended
  2022-502492-32-00 7 2023-02-03 Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Defici
• A study to learn how well the drug EDP-938 works and how safe it is for non-hospitalized Adults with Acute Respiratory Syncytial Virus Infec … Ended
  2024-513861-38-00 4 2023-02-02 Respiratory syncytial virus (RSV)
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A multi-center study to evaluate the safety, tolerability and efficacy of TIN816 in patients at risk for acute kidney injury following a car … Ended
  2024-511621-64-00 4 2023-01-18 Acute kidney injury
• Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended
  2023-504112-15-00 4 2023-01-04 Metastatic Non-Small Cell Lung Cancer
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 9 2022-09-02 Advanced/metastatic hepatocellular carcinoma (HCC)
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance … Ended
  2024-514293-46-00 4 2022-07-07 Unresectable locally advanced or metastatic urothelial cancer

Showing 577–600 of 662 trials